| 000 | 01525nam a2200289 i 4500 | ||
|---|---|---|---|
| 005 | 20230911142604.0 | ||
| 008 | 160211s2007 muaa|||| |||| 00| 0 eng d | ||
| 020 | _a0805338195 | ||
| 020 | _a9780805338195 | ||
| 040 |
_aEG-NcFUE _erda |
||
| 082 | 0 | 4 |
_223 _a616.042 _bC.M.G |
| 100 | 1 |
_aColavito, Mary C. _eauthor |
|
| 245 | 1 | 0 |
_aGene therapy / _cMary C. Colavito. |
| 264 | 1 |
_aSan Francisco : _bPearson, _c[2007], |
|
| 300 |
_aiv, 42 pages : _billustrations ; _c24 cm. |
||
| 336 |
_atext _2rdacontent |
||
| 337 |
_aunmediated _2rdamedia |
||
| 338 |
_avolume _2rdacarrier |
||
| 490 | 0 | _aBenjamin/Cummings special topics in biology series | |
| 500 | _apharmacy bookfair2016 | ||
| 504 | _aIncludes bibliographical references. | ||
| 505 | 0 | _aRealizing the promise of gene therapy : successes, setbacks, and challenges -- Gene therapy methods. Identifying a disease that is likely to respond to gene therapy ; Isolating a functional copy of the gene ; Incorporating the gene into a carrier for gene delivery ; Determining whether the gene product is made -- Partial successes and ongoing trials. Gene therapy for severe combined immune deficiency (ADA-SCID) ; Gene therapy for cystic fibrosis ; Gene therapy for canavan disease -- Setbacks. Immune reactions targeting cells carrying the vector ; Inadvertent activation of cancer causing genes by a vector ; Insufficient numbers of cells producing the gene product. | |
| 650 | 0 | _aGene therapy. | |
| 650 | 0 | _aGenetic Therapy. | |
| 942 |
_2ddc _cBK |
||
| 999 |
_c10422 _d10422 |
||